We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Stocks to Focus on Global Biotechnology Reagents Market
Read MoreHide Full Article
Advancement in the field of biotechnology along with growing need of reagents in drug testing and stem cell research is pushing demand for biotechnology reagents worldwide. Therefore it would be prudent to take a look at a couple of stocks operating in the segment that are poised to gain from the trend.
Promising Growth for Biotechnology Reagents
The global biotechnology reagents market is poised for impressive growth, according to a reportby research firm Research and Markets. Increasing research on stem cells is a major factor pushing this industry. Per the research firm, the industry is set to witness a compound annual growth rate of about 9% during the forecast period 2019-2023.
Trends Driving Demand for Reagents
The biotechnology sector has been doing remarkably well this year, despite the lackluster performance by the broader healthcare sector. In fact, the SPDR S&P Biotech ETF (XBI) has outperformed the broader Health Care Select Sector SPDR Fund (XLV) on a year-to-date basis. The former has increased 15.2% while the latter has only moved 6.2% higher.
The increasing use of biotechnology reagents is a prominent reason behind the significant growth of the biotechnology sector. Reagents are a crucial element in the area of drug discovery and these have high demand in research, therapeutics and commercial applications.
This is why biotechnology reagents have attracted heavy investments in research and development lately and will continue to do so. In fact, reagents have a rather broad spectrum of application in stem cell research. These are used as biomarkers to visualize cell and tissue lines.
Stem cell research is growing by leaps and bounds, thanks to its many benefits that include treatment of an array of diseases. Therefore with the rise in stem cell research, demand for reagents is poised to rise as well.
Our Choices
We have therefore chosen four stocks that are revolutionizing the global biotechnology reagents market which investors could consider in their portfolio. All of these stocks carry a Zacks Rank #2 (Buy) or 3 (Hold).
Agilent Technologies, Inc. (A - Free Report) is an analytical laboratory instrument manufacturing company. The company’s Dako brand offers high-quality reagents, diagnostic antibodies, instruments and software solutions that assist in the treatment of cancer patients.
Agilent Technologies carries a Zacks Rank #2. The company’s stock price has outperformed the Zacks Electronics - Testing Equipment market on an annualized basis (+10.4% vs +0.6%). The Zacks Consensus Estimate for its current-year earnings has risen 1% over the past 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Danaher Corporation (DHR - Free Report) is a conglomerate and manufacturer of medical products. The company’s life sciences wing offers sophisticated equipment for biological research.
Danaher carries a Zacks Rank #2. The company’s stock price has already outperformed the Zacks Diversified Operations market on a year-to-date basis (+34.9% vs -5.2%). The Zacks Consensus Estimate for its current-year earnings has risen 0.2% over the past 60 days.
Thermo Fisher Scientific Inc. (TMO - Free Report) is a manufacturer of analytical instruments, equipment and reagents.
Thermo Fisher Scientific carries a Zacks Rank #3. The company’s stock price has outperformed the Zacks Medical - Instruments market on a year-to-date basis (+21.3% vs -5.7%). The Zacks Consensus Estimate for its current-year earnings has risen 0.4% over the past 60 days.
General Electric Company’s (GE - Free Report) life sciences wing operates in the cell and gene therapy industry. The company offers end-to-end solutions that include software and equipment that drive uniformity to dependable reagents.
General Electric carries a Zacks Rank #3. The stock price has outperformed the Zacks Diversified Operations market on a year-to-date basis (+24.5% vs +20.3%). The Zacks Consensus Estimate for its current-year earnings has risen 1.6% over the past 60 days.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
4 Stocks to Focus on Global Biotechnology Reagents Market
Advancement in the field of biotechnology along with growing need of reagents in drug testing and stem cell research is pushing demand for biotechnology reagents worldwide. Therefore it would be prudent to take a look at a couple of stocks operating in the segment that are poised to gain from the trend.
Promising Growth for Biotechnology Reagents
The global biotechnology reagents market is poised for impressive growth, according to a reportby research firm Research and Markets. Increasing research on stem cells is a major factor pushing this industry. Per the research firm, the industry is set to witness a compound annual growth rate of about 9% during the forecast period 2019-2023.
Trends Driving Demand for Reagents
The biotechnology sector has been doing remarkably well this year, despite the lackluster performance by the broader healthcare sector. In fact, the SPDR S&P Biotech ETF (XBI) has outperformed the broader Health Care Select Sector SPDR Fund (XLV) on a year-to-date basis. The former has increased 15.2% while the latter has only moved 6.2% higher.
The increasing use of biotechnology reagents is a prominent reason behind the significant growth of the biotechnology sector. Reagents are a crucial element in the area of drug discovery and these have high demand in research, therapeutics and commercial applications.
This is why biotechnology reagents have attracted heavy investments in research and development lately and will continue to do so. In fact, reagents have a rather broad spectrum of application in stem cell research. These are used as biomarkers to visualize cell and tissue lines.
Stem cell research is growing by leaps and bounds, thanks to its many benefits that include treatment of an array of diseases. Therefore with the rise in stem cell research, demand for reagents is poised to rise as well.
Our Choices
We have therefore chosen four stocks that are revolutionizing the global biotechnology reagents market which investors could consider in their portfolio. All of these stocks carry a Zacks Rank #2 (Buy) or 3 (Hold).
Agilent Technologies, Inc. (A - Free Report) is an analytical laboratory instrument manufacturing company. The company’s Dako brand offers high-quality reagents, diagnostic antibodies, instruments and software solutions that assist in the treatment of cancer patients.
Agilent Technologies carries a Zacks Rank #2. The company’s stock price has outperformed the Zacks Electronics - Testing Equipment market on an annualized basis (+10.4% vs +0.6%). The Zacks Consensus Estimate for its current-year earnings has risen 1% over the past 60 days. You can see the complete list of today’s Zacks #1 Rank stocks here.
Danaher Corporation (DHR - Free Report) is a conglomerate and manufacturer of medical products. The company’s life sciences wing offers sophisticated equipment for biological research.
Danaher carries a Zacks Rank #2. The company’s stock price has already outperformed the Zacks Diversified Operations market on a year-to-date basis (+34.9% vs -5.2%). The Zacks Consensus Estimate for its current-year earnings has risen 0.2% over the past 60 days.
Thermo Fisher Scientific Inc. (TMO - Free Report) is a manufacturer of analytical instruments, equipment and reagents.
Thermo Fisher Scientific carries a Zacks Rank #3. The company’s stock price has outperformed the Zacks Medical - Instruments market on a year-to-date basis (+21.3% vs -5.7%). The Zacks Consensus Estimate for its current-year earnings has risen 0.4% over the past 60 days.
General Electric Company’s (GE - Free Report) life sciences wing operates in the cell and gene therapy industry. The company offers end-to-end solutions that include software and equipment that drive uniformity to dependable reagents.
General Electric carries a Zacks Rank #3. The stock price has outperformed the Zacks Diversified Operations market on a year-to-date basis (+24.5% vs +20.3%). The Zacks Consensus Estimate for its current-year earnings has risen 1.6% over the past 60 days.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>